HighVista Strategies’s Puma Biotechnology PBYI Stock Holding History

HighVista Strategies’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,972	Closed	-$84K	–	102
2021 Q3	$84K	Buy	+11,972	New	+$89.6K	0.06%	114

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HighVista Strategies's PBYI Position: Q4 2021 in Review

HighVista Strategies sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 11,972 shares — an estimated $84K sold.

HighVista Strategies first reported a position in PBYI in Q3 2021 and held it in 1 quarter. The position peaked at $84K in Q3 2021. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

HighVista Strategies reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
HighVista Strategies sold 11,972 Puma Biotechnology shares in Q4 2021, an estimated $84K.
HighVista Strategies first reported a position in Puma Biotechnology in Q3 2021 and held it in 1 quarter.
HighVista Strategies's Puma Biotechnology position peaked at $84K in Q3 2021.
102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.